FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180446815> ?p ?o ?g. }

• W3180446815 abstract "Background: Neuroendocrine neoplasias (NENs) are a heterogeneous group of rare tumors scattered throughout the body. For nonresectable advanced NENs, the main treatment approaches including somatostatin analog, multiple TKIs, mTOR inhibitors and peptide receptor radionuclide therapy, whereas platinum-based chemotherapy is the main treatment for advanced high-grade and poorly differentiated NECs. Currently, there is no standard second-line treatment for NECs when disease progression. ctDNA as a non-invasive diagnostic avenue, which might potentially provide treatment guidance in NENs.Methods: We queried consecutive data from 40 NENs patients who underwent a targeted next-generation sequencing (NGS) assay performed by 3DMed Clinical Laboratory Inc., a College of American Pathologists (CAP) certified and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory of 3D Medicines Inc. between January, 2017 and June, 2020 in China, to identify the alterations detected in ctDNA. The alterations were classified based on the ranking in the OncoKB database as of January 2020.Results: In total, 40 of NENs patients detected with at least one alteration in ctDNA. The median age was 54 years, including 28 males and 12 females. Overall, 40.0% of patients had a Level 1 alteration, 22.5% of patients had a Level 2 alteration, and 22.5% of patients had a R1 alteration (selected alterations were outlined in Table).Conclusion: ctDNA analysis could provide information of alterations with strong evidence for targeted therapy or drug resistance based on the OncoKB database classification for NENs. Though the alterations are associated with other specific cancer types, the alterations still illustrate a part of NENs patients might have chance to be benefited from targeted therapy.AlterationsNumber of patients (%)Total Level 1 Alterations16 (40.0%)PIK3CA7 (17.5%)BRAF V600E2 (5.0%)BRCA22 (5.0%)MSI-H1 (2.5%)Total Level 2 Alterations9 (22.5%)ERBB2 activating4 (10.0%)MET amplication1 (2.5%)Total Level R1 alterations9 (22.5%)KRAS mut9 (22.5%)Citation Format: Kunli Du, Xueke She, Depei Huang, Xudong Shen, Hushan Zhang, Jianyong Zheng. Usage of ctDNA analysis to identify alterations with strong evidence for response or resistance to targeted therapy in patients with NENs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2228." @default.
• W3180446815 created "2021-07-19" @default.
• W3180446815 creator A5004648803 @default.
• W3180446815 creator A5028470655 @default.
• W3180446815 creator A5035653873 @default.
• W3180446815 creator A5041511388 @default.
• W3180446815 creator A5063206909 @default.
• W3180446815 creator A5091771176 @default.
• W3180446815 date "2021-07-01" @default.
• W3180446815 modified "2023-10-15" @default.
• W3180446815 title "Abstract 2228: Usage of ctDNA analysis to identify alterations with strong evidence for response or resistance to targeted therapy in patients with NENs" @default.
• W3180446815 doi "https://doi.org/10.1158/1538-7445.am2021-2228" @default.
• W3180446815 hasPublicationYear "2021" @default.
• W3180446815 type Work @default.
• W3180446815 sameAs 3180446815 @default.
• W3180446815 citedByCount "0" @default.
• W3180446815 crossrefType "proceedings-article" @default.
• W3180446815 hasAuthorship W3180446815A5004648803 @default.
• W3180446815 hasAuthorship W3180446815A5028470655 @default.
• W3180446815 hasAuthorship W3180446815A5035653873 @default.
• W3180446815 hasAuthorship W3180446815A5041511388 @default.
• W3180446815 hasAuthorship W3180446815A5063206909 @default.
• W3180446815 hasAuthorship W3180446815A5091771176 @default.
• W3180446815 hasConcept C121608353 @default.
• W3180446815 hasConcept C126322002 @default.
• W3180446815 hasConcept C143998085 @default.
• W3180446815 hasConcept C2776694085 @default.
• W3180446815 hasConcept C2779066768 @default.
• W3180446815 hasConcept C2781230642 @default.
• W3180446815 hasConcept C535046627 @default.
• W3180446815 hasConcept C71924100 @default.
• W3180446815 hasConceptScore W3180446815C121608353 @default.
• W3180446815 hasConceptScore W3180446815C126322002 @default.
• W3180446815 hasConceptScore W3180446815C143998085 @default.
• W3180446815 hasConceptScore W3180446815C2776694085 @default.
• W3180446815 hasConceptScore W3180446815C2779066768 @default.
• W3180446815 hasConceptScore W3180446815C2781230642 @default.
• W3180446815 hasConceptScore W3180446815C535046627 @default.
• W3180446815 hasConceptScore W3180446815C71924100 @default.
• W3180446815 hasLocation W31804468151 @default.
• W3180446815 hasOpenAccess W3180446815 @default.
• W3180446815 hasPrimaryLocation W31804468151 @default.
• W3180446815 hasRelatedWork W1970832899 @default.
• W3180446815 hasRelatedWork W2044328190 @default.
• W3180446815 hasRelatedWork W2058636175 @default.
• W3180446815 hasRelatedWork W2092151800 @default.
• W3180446815 hasRelatedWork W2316766300 @default.
• W3180446815 hasRelatedWork W2321734596 @default.
• W3180446815 hasRelatedWork W2328465541 @default.
• W3180446815 hasRelatedWork W2387957804 @default.
• W3180446815 hasRelatedWork W2741866105 @default.
• W3180446815 hasRelatedWork W95026785 @default.
• W3180446815 isParatext "false" @default.
• W3180446815 isRetracted "false" @default.
• W3180446815 magId "3180446815" @default.
• W3180446815 workType "article" @default.